Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891106 · ClinicalTrials.gov registry record
AONDA Therapeutic Indication Study I
A clinical trial, sponsored by Alcon Research.
- Completed
- Registry status
- 55
- Enrollment target
NCT05891106: Completed study, sponsored by Alcon Research.
NCT05891106 is a clinical trial that has completed, run by Alcon Research. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05891106 has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
This study will be used to support assessment of AIR OPTIX® NIGHT \& DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.
Primary Outcome
The Investigator will review the subject's chart and document change from baseline in corneal pain at the Follow-up visit as "improved, similar, or worsened." The Baseline Visit is defined as the first visit where the AONDA therapeutic contact lens was placed on eye as part of a treatment plan for an ocular condition. The Follow-up Visit is defined as the first visit where the AONDA therapeutic contact lens was removed from the eye, or the first visit following the removal of the contact lens if
Interventions
- DEVICE Lotrafilcon A contact lenses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2023-07-10 |
What the finished NCT05891106 record still lists
NCT05891106 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Lotrafilcon A contact lenses is the first listed.
NCT05891106 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05891106 about?
NCT05891106 is a clinical study titled "AONDA Therapeutic Indication Study I". This study will be used to support assessment of AIR OPTIX® NIGHT \& DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.
What is the current status of trial NCT05891106?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2023-06-28. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT05891106?
The interventions under investigation include: Lotrafilcon A contact lenses (DEVICE).
Who is sponsoring clinical trial NCT05891106?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI